BioCentury
ARTICLE | Clinical News

PharmaMar reports Phase II response data for Zepsyre in Ewing's sarcoma

November 30, 2017 11:45 PM UTC

PharmaMar S.A. (Madrid:PHM) reported data from 25 patients with Ewing’s sarcoma who received ≤2 prior chemotherapeutic treatments in a Phase II trial showing that 3.2 mg/m2 Zepsyre lurbinectedin (PM01183, PM1183) given every 3 weeks led to a disease control rate (DCR) of 60%, including 3 partial responses, plus 12 cases of stable disease. The median duration of response was 2.9 months. Data were presented at the Connective Tissue Oncology Society meeting in Wailea.

The open-label, international basket trial is to enroll about 325 patients with advanced solid tumors, including small cell lung cancer (SCLC), head and neck cancer, neuroendocrine tumors, biliary tract cancer, endometrial cancer, BRCA1- and BRCA2-associated metastatic breast cancer, carcinoma of unknown primary site, germ cell tumors, and Ewing's family of tumors...